Artelo Biosciences, Inc.

NasdaqCM:ARTL Stock Report

Market Cap: US$3.1m

Artelo Biosciences Management

Management criteria checks 2/4

Artelo Biosciences' CEO is Greg Gorgas, appointed in Apr 2017, has a tenure of 7.67 years. total yearly compensation is $994.10K, comprised of 48.8% salary and 51.2% bonuses, including company stock and options. directly owns 0.63% of the company’s shares, worth $19.83K. The average tenure of the management team and the board of directors is 6.1 years and 6.1 years respectively.

Key information

Greg Gorgas

Chief executive officer

US$994.1k

Total compensation

CEO salary percentage48.8%
CEO tenure7.7yrs
CEO ownership0.6%
Management average tenure6.1yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Artelo jumps 21% as publication highlights pre-clinical data on drug platform

Aug 16

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Mar 28
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy

Mar 09

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Nov 02
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Relief For Cancer Patients In Artelo Bioscience Pipeline

Jul 12

Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

May 20
Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans

Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

Feb 04
Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?

INO, VXRT, BTU and TTM among premarket gainers

Feb 02

Artelo Biosciences EPS misses by $0.04

Jan 14

Artelo Biosciences on go with cancer appetite recovery study

Nov 16

CEO Compensation Analysis

How has Greg Gorgas's remuneration changed compared to Artelo Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

-US$10m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$994kUS$485k

-US$9m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$9m

Mar 31 2023n/an/a

-US$10m

Dec 31 2022US$655kUS$440k

-US$10m

Sep 30 2022n/an/a

-US$13m

Jun 30 2022n/an/a

-US$13m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$1mUS$142k

-US$12m

Nov 30 2021n/an/a

-US$9m

Aug 31 2021n/an/a

-US$7m

May 31 2021n/an/a

-US$7m

Feb 28 2021n/an/a

-US$5m

Nov 30 2020n/an/a

-US$5m

Aug 31 2020US$581kUS$431k

-US$5m

May 31 2020n/an/a

-US$4m

Feb 29 2020n/an/a

-US$4m

Nov 30 2019n/an/a

-US$3m

Aug 31 2019US$347kUS$209k

-US$2m

May 31 2019n/an/a

-US$2m

Feb 28 2019n/an/a

-US$2m

Nov 30 2018n/an/a

-US$3m

Aug 31 2018US$75kUS$75k

-US$2m

Compensation vs Market: Greg's total compensation ($USD994.10K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Greg's compensation has increased whilst the company is unprofitable.

CEO

Greg Gorgas (61 yo)

7.7yrs

Tenure

US$994,095

Compensation

Mr. Gregory D. Gorgas, also known as Greg, M.B.A. has been the Chief Executive Officer, President, Chief Financial Officer, Secretary and Treasurer of Artelo Biosciences, Inc. since April 3, 2017. He has e...

Leadership Team

NamePositionTenureCompensationOwnership
Gregory Gorgas
President7.7yrsUS$994.10k0.63%
$ 19.8k
Andrew Yates
Senior VP & Chief Scientific Officer3.8yrsno datano data
Steven Reich
Chief Medical Officer6.7yrsno datano data
Jason Baybutt
Senior Vice President of Finance5.6yrsno datano data

6.1yrs

Average Tenure

61yo

Average Age

Experienced Management: ARTL's management team is seasoned and experienced (6.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Gregory Gorgas
President7.7yrsUS$994.10k0.63%
$ 19.8k
Connie Matsui
Independent Chairperson of the Board7.6yrsUS$74.41k0.12%
$ 3.7k
Robert Emanuele
Independent Director7.3yrsUS$41.91k0.026%
$ 809.0
Tamara Favorito
Independent Director3.8yrsUS$55.80kno data
Steven Kelly
Independent Director7.6yrsUS$57.41k0.026%
$ 809.0
Iwao Ojima
Member of the Advisory Board3.2yrsno datano data
Gregory Reyes
Independent Director4.1yrsUS$42.41kno data
Richard Porter
Member of Scientific Advisory Board4yrsno datano data
Douglas Blayney
Independent Director7.4yrsUS$45.91k0.026%
$ 809.0
Steven Laviolette
Member of Scientific Advisor Boardno datano datano data
Martin Kaczocha
Member of Scientific Advisory Board5yrsno datano data

6.1yrs

Average Tenure

70yo

Average Age

Experienced Board: ARTL's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 20:14
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Artelo Biosciences, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason KolbertD. Boral Capital LLC.
Vernon BernardinoH.C. Wainwright & Co.
Matthew KaplanLadenburg Thalmann & Company